2024

• Riley, N., Wong, E., Walker, R., Drudge, C., Nelson, M., Barnett, M. (2024). Comparative efficacy of ofatumumab versus oral therapies for relapsing multiple sclerosis patients using propensity score analyses and simulated treatment comparisons. Therapeutic Advances in Neurological Disorders, 17. [More Information]
• Klistorner, S., Barnett, M., Klistorner, A. (2024). Longitudinal enlargement of choroid plexus is associated with chronic lesion expansion and neurodegeneration in RRMS patients. Multiple Sclerosis Journal. [More Information]
• Kyle, K., Peters, J., Jonker, B., Barnett, Y., Maamary, J., Barnett, M., Maller, J., Wang, C., Tisch, S. (2024). Magnetic Resonance–Guided Focused Ultrasound for Treatment of Essential Tremor: Ventral Intermediate Nucleus Ablation Alone or Additional Posterior Subthalamic Area Lesioning? Movement Disorders Clinical Practice, 11(5), 504-514. [More Information]
• Selmaj, K., Cree, B., Barnett, M., Thompson, A., Hartung, H. (2024). Multiple sclerosis: time for early treatment with high-efficacy drugs. Journal of Neurology, 271(1), 105-115. [More Information]
• Hardy, T., Aouad, P., Barnett, M., Blum, S., Broadley, S., Carroll, W., Crimmins, D., Griffiths, D., Hodgkinson, S., Lechner-Scott, J., et al (2024). Onboarding of siponimod in secondary progressive multiple sclerosis patients in Australia: Novel, real-world evidence from the MSGo digital support programme. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 10(1), 1-11. [More Information]
• Trewin, B., Dale, R., Qiu, J., Chu, M., Jeyakumar, N., Cruz, F., Andersen, J., Siriratnam, P., Ma, K., Hardy, T., Barnett, M., Reddel, S., Brilot-Turville, F., Ramanathan, S., et al (2024). Oral corticosteroid dosage and taper duration at onset in myelin oligodendrocyte glycoprotein antibody-associated disease influences time to first relapse. Journal of Neurology, Neurosurgery and Psychiatry, 95(11), 1054-1063. [More Information]
• Mate, S., Soutter, M., Liaros, J., Hackett, D., Barnett, M., Fiatarone Singh, M., Fornusek, C. (2024). The effects of hybrid functional electrical stimulation interval training on aerobic fitness and fatigue in people with advanced multiple sclerosis: An exploratory pilot training study. Multiple Sclerosis and Related Disorders, 83, 105458. [More Information]
• Foong, Y., Jimenez Sanchez, S., Darby, D., Dobay, P., van Beek, J., Hyde, R., Bundell, C., van der Walt, A., Merlo, D., Gresle, M., Barnett, M., et al (2024). The Patient-Determined Disease Steps scale is not interchangeable with the Expanded Disease Status Scale in mild to moderate multiple sclerosis. European Journal of Neurology, 31(1), e16046. [More Information]
• Butzkueven, H., Carroll, W., Mitchell, P., Hardy, T., Al Macdonell, R., McCombe, P., Lee, A., Kalincik, T., van der Walt, A., Lin, M., Barnett, M., et al (2024). Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome. Brain, 147(4), 1206-1215. [More Information]

2023

• Barnett, M., Wang, D., Beadnall, H., Bischof, A., Brunacci, D., Butzkueven, H., Brown, J., Cabezas Grebol, M., Das, T., Dugal, T., Klistorner, A., Kyle, K., Tang, Z., Zhan, G., Wang, C., et al (2023). A real-world clinical validation for AI-based MRI monitoring in multiple sclerosis. npj Digital Medicine, 6(1). [More Information]
• Hartung, H., Cree, B., Barnett, M., Meuth, S., Bar-Or, A., Steinman, L. (2023). Bioavailable central nervous system disease-modifying therapies for multiple sclerosis. Frontiers in Immunology, 14. [More Information]
• Klistorner, S., van der Walt, A., Barnett, M., Butzkueven, H., Kolbe, S., Parratt, J., Yiannikas, C., Klistorner, A. (2023). Choroid plexus volume is enlarged in clinically isolated syndrome patients with optic neuritis. Multiple Sclerosis Journal. [More Information]
• Roos, I., Diouf, I., Sharmin, S., Horakova, D., Havrdova, E., Patti, F., Shaygannejad, V., Ozakbas, S., Izquierdo, G., Eichau, S., Barnett, M., et al (2023). Comparative effectiveness in multiple sclerosis: A methodological comparison. Multiple Sclerosis Journal, 29(3), 326-332. [More Information]
• Zhu, C., Kalincik, T., Horakova, D., Zhou, Z., Buzzard, K., Skibina, O., Alroughani, R., Izquierdo, G., Eichau, S., Kuhle, J., Barnett, M., et al (2023). Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation. JAMA Neurology, 80(7), 739-748. [More Information]
• Liu, D., Zhang, C., Song, Y., Huang, H., Wang, C., Barnett, M., Cai, W. (2023). Decompose to Adapt: Cross-Domain Object Detection Via Feature Disentanglement. IEEE Transactions on Multimedia, 25, 1333-1344. [More Information]
• Maher, C., Tang, Z., D'Souza, A., Cabezas Grebol, M., Cai, W., Barnett, M., Kavehei, O., Wang, C., Nikpour (Mohamed), A. (2023). Deep learning distinguishes connectomes from focal epilepsy patients and controls: feasibility and clinical implications. Brain Communications, 5(6), fcad294. [More Information]
• Daruwalla, C., Shaygannejad, V., Ozakbas, S., Havrdova, E., Horakova, D., Alroughani, R., Boz, C., Patti, F., Barnett, M., Hardy, T., et al (2023). Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 29(7), 875-883. [More Information]
• Zhan, G., Wang, D., Cabezas Grebol, M., Bai, L., Kyle, K., Ouyang, W., Barnett, M., Wang, C. (2023). Learning from pseudo-labels: deep networks improve consistency in longitudinal brain volume estimation. Frontiers in Neuroscience, 17, 1196087. [More Information]
• Halmagyi, G., Parker, G., Chen, L., Welgampola, M., Watson, J., Barnett, M., Todd, M., El-Wahsh, S., Rose, V., Stoodley, M., et al (2023). Progressive loss of hearing and balance in superficial siderosis due to occult spinal dural defects. European Archives of Oto-Rhino-Laryngology, 280(2), 633-641. [More Information]
• Pittock, S., Barnett, M., Bennett, J., Berthele, A., De Sèze, J., Levy, M., Nakashima, I., Oreja-Guevara, C., Palace, J., Paul, F., et al (2023). Ravulizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder. Annals of Neurology. [More Information]
• Wang, D., Jin, R., Shieh, C., Ng, A., Pham, H., Dugal, T., Barnett, M., Winoto, L., Wang, C., Barnett, Y. (2023). Real world validation of an AI-based CT hemorrhage detection tool. Frontiers in Neurology, 14. [More Information]
• Sharmin, S., Roos, I., Simpson-Yap, S., Malpas, C., Sanchez, M., Ozakbas, S., Horakova, D., Havrdova, E., Barnett, M., Hardy, T., et al (2023). The risk of secondary progressive multiple sclerosis is geographically determined but modifiable. Brain, 146(11), 4633-4644. [More Information]

2022

• Sesel, A., Sharpe, L., Beadnall, H., Barnett, M., Szabo, M., Naismith, S. (2022). A randomized controlled trial of a web-based mindfulness programme for people with MS with and without a history of recurrent depression. Multiple Sclerosis Journal, 28(9), 1392-1401. [More Information]
• D'Souza, A., Wang, C., Tu, S., Soligo, D., Kiernan, M., Barnett, M., Calamante, F. (2022). A robust framework for characterising diffusion metrics of the median and ulnar nerves: Exploiting state-of-the-art tracking methods. Journal of the Peripheral Nervous System, 27(1), 67-83. [More Information]
• Klistorner, S., Barnett, M., Parratt, J., Yiannikas, C., Graham, S., Klistorner, A. (2022). Choroid plexus volume in multiple sclerosis predicts expansion of chronic lesions and brain atrophy. Annals of Clinical and Translational Neurology, 9(10), 1528-1537. [More Information]
• Zhu, C., Zhou, Z., Roos, I., Merlo, D., Kalincik, T., Ozakbas, S., Skibina, O., Kuhle, J., Hodgkinson, S., Boz, C., Barnett, M., et al (2022). Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 93(12), 1330-1337. [More Information]
• Triplett, J., Qiu, J., O'Brien, B., Gopinath, S., Trewin, B., Spring, P., Shaffi, M., Ip, J., Chan, F., Chen, L., Beadnall, H., Barnett, M., Reddel, S., Hardy, T., et al (2022). Diagnosis, differential diagnosis and misdiagnosis of Susac syndrome. European Journal of Neurology, 29(6), 1771-1781. [More Information]
• Tang, Z., Cabezas Grebol, M., D'Souza, A., Calamante, F., Liu, D., Barnett, M., Wang, C., Cai, W. (2022). Diffusion MRI Fibre Orientation Distribution Inpainting. Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics), : Springer Verlag.
• Klistorner, S., Barnett, M., Yiannikas, C., Barton, J., Parratt, J., You, Y., Graham, S., Klistorner, A. (2022). Expansion of chronic MS lesions is associated with an increase of radial diffusivity in periplaque white matter. Multiple Sclerosis Journal, 28(5), 697-706. [More Information]
• Zeng, R., Lv, J., Wang, H., Zhou, L., Barnett, M., Calamante, F., Wang, C. (2022). FOD-Net: A deep learning method for fiber orientation distribution angular super resolution. Medical Image Analysis, 79, 102431. [More Information]
• Räuber, S., Korsen, M., Huntemann, N., Rolfes, L., Müntefering, T., Dobelmann, V., Hermann, A., Kölsche, T., Von Wnuck Lipinski, K., Schroeter, C., Barnett, M., Hartung, H., et al (2022). Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab. Journal of Neurology, Neurosurgery and Psychiatry, 93(9), 978-985. [More Information]
• Klistorner, A., Klistorner, S., You, Y., Graham, S., Yiannikas, K., Parratt, J., Barnett, M. (2022). Long-term Effect of Permanent Demyelination on Axonal Survival in Multiple Sclerosis. Neurology: Neuroimmunology and Neuroinflammation, 9(3). [More Information]
• Klistorner, S., Barnett, M., Klistorner, A. (2022). Mechanisms of central brain atrophy in multiple sclerosis. Multiple Sclerosis Journal, 28(13), 2038-2045. [More Information]
• Barnett, M., Barnett, Y., Reddel, S. (2022). MRI and laboratory monitoring of disease-modifying therapy efficacy and risks. Current Opinion In Neurology, 35(3), 278-285. [More Information]
• Ma, Y., Zhang, C., Cabezas Grebol, M., Song, Y., Tang, Z., Liu, D., Cai, W., Barnett, M., Wang, C. (2022). Multiple Sclerosis Lesion Analysis in Brain Magnetic Resonance Images: Techniques and Clinical Applications. IEEE Journal of Biomedical and Health Informatics, 26(6), 2680-2692. [More Information]
• Cree, B., Hartung, H., Barnett, M. (2022). New drugs for multiple sclerosis: New treatment algorithms. Current Opinion In Neurology, 35(3), 262-270. [More Information]
• Bukhari, W., Khalilidehkordi, E., Mason, D., Barnett, M., Taylor, B., Fabis-Pedrini, M., Kermode, A., Subramanian, S., Waters, P., Broadley, S. (2022). NMOSD and MS prevalence in the Indigenous populations of Australia and New Zealand. Journal of Neurology, 269(2), 836-845. [More Information]
• Zhong, M., van der Walt, A., Stankovich, J., Kalincik, T., Buzzard, K., Skibina, O., Boz, C., Hodgkinson, S., Slee, M., Lechner-Scott, J., Barnett, M., et al (2022). Prediction of multiple sclerosis outcomes when switching to ocrelizumab. Multiple Sclerosis Journal, 28(6), 958-969. [More Information]
• Law, L., Barnett, M., Barnett, Y., Masters, L., Beadnall, H., Hardy, T., Reddel, S. (2022). Presumptive isolated neurosarcoidosis involving eloquent structures: An argument for empirical TNF-α inhibition. Journal of Neuroimmunology, 372. [More Information]
• Clarke, L., Bukhari, W., O'Gorman, C., Khalilidehkordi, E., Arnett, S., Woodhall, M., Prain, K., Parratt, J., Barnett, M., Marriott, M., et al (2022). Response to treatment in NMOSD: the Australasian experience. Multiple Sclerosis and Related Disorders, 58. [More Information]
• Palmer, J., Wang, C., Kong, D., Cespedes, M., Pye, J., Hickie, I., Barnett, M., Naismith, S. (2022). Rest-activity rhythms and tract specific white matter lesions in older adults at risk for cognitive decline. Molecular Psychiatry, 27(8), 3410-3416. [More Information]
• Makowiecki, K., Stevens, N., Cullen, C., Zarghami, A., Nguyen, P., Johnson, L., Rodger, J., Hinder, M., Barnett, M., Young, K., et al (2022). Safety of low-intensity repetitive transcranial magneTic brAin stimUlation foR people living with mUltiple Sclerosis (TAURUS): study protocol for a randomised controlled trial. Trials, 23(1). [More Information]
• Maher, C., D'Souza, A., Barnett, M., Kavehei, O., Wang, C., Nikpour (Mohamed), A. (2022). Structure-Function Coupling Reveals Seizure Onset Connectivity Patterns. Applied Sciences, 12(20). [More Information]
• Merlo, D., Kalincik, T., Zhu, C., Gresle, M., Lechner-Scott, J., Kilpatrick, T., Barnett, M., Taylor, B., Buzzard, K., Darby, D., et al (2022). Subjective versus objective performance in people with multiple sclerosis using the MSReactor computerised cognitive tests. Multiple Sclerosis and Related Disorders, 58, 103393. [More Information]
• Klistorner, S., Barnett, M., Graham, S., Wang, C., Klistorner, A. (2022). The expansion and severity of chronic MS lesions follows a periventricular gradient. Multiple Sclerosis Journal, 28(10), 1504-1514. [More Information]
• Anderson, S., Dunkley, S., Barnett, M., Kershaw, G. (2022). Thinking fast not slow: a fast-acting, high-titre acquired factor VIII inhibitor. Pathology, 54(3), 363-365. [More Information]
• Hardy, T., Parratt, J., Beadnall, H., Blum, S., Macdonell, R., Beran, R., Shuey, N., Lee, A., Carroll, W., Shaw, C., Barnett, M., Vucic, S., et al (2022). Treatment satisfaction in patients with relapsing-remitting multiple sclerosis initiated on teriflunomide in routine clinical practice: Australian observational data. BMJ Neurology Open, 4(2). [More Information]
• Winkelmann, A., Loebermann, M., Barnett, M., Hartung, H., Zettl, U. (2022). Vaccination and immunotherapies in neuroimmunological diseases. Nature Reviews Neurology, 18(5), 289-306. [More Information]
• Räuber, S., Willison, A., Korsen, M., Kölsche, T., Golombeck, K., Plaack, B., Schüller, J., Huntemann, N., Rolfes, L., Schroeter, C., Barnett, M., Hartung, H., et al (2022). Vaccine-based clinical protection against SARS-CoV-2 infection and the humoral immune response: A 1-year follow-up study of patients with multiple sclerosis receiving ocrelizumab. Frontiers in Immunology, 13. [More Information]
• Lopez, J., Houston, S., Tea, F., Merheb, V., Lee, F., Smith, S., McDonald, D., Zou, A., Liyanage, G., Pilli, D., Denkova, M., Barnett, M., Reddel, S., Ramanathan, S., Dale, R., Brown, D., Brilot-Turville, F., et al (2022). Validation of a Flow Cytometry Live Cell-Based Assay to Detect Myelin Oligodendrocyte Glycoprotein Antibodies for Clinical Diagnostics. Journal of Applied Laboratory Medicine, 7(1), 12-25. [More Information]
• Maher, C., D'Souza, A., Zeng, R., Barnett, M., Kavehei, O., Nikpour (Mohamed), A., Wang, C. (2022). White matter alterations in focal to bilateral tonic-clonic seizures. Frontiers in Neurology, 13. [More Information]

2021

• Khurana, V., Jithoo, R., Barnett, M. (2021). Aerospace Implications of Key Neurological Conditions. Aerospace Medicine and Human Performance, 92(2), 113-119. [More Information]
• Merlo, D., Stankovich, J., Bai, C., Kalincik, T., Zhu, C., Gresle, M., Lechner-Scott, J., Kilpatrick, T., Barnett, M., Taylor, B., et al (2021). Association between cognitive trajectories and disability progression in patients with relapsing-remitting multiple sclerosis. Neurology, 97(20), E2020-E2031. [More Information]
• Chaseling, G., Filingeri, D., Allen, D., Barnett, M., Vucic, S., Davis, S., Jay, O. (2021). Blunted sweating does not alter the rise in core temperature in people with multiple sclerosis exercising in the heat. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 320(3), 258-267. [More Information]
• Barnett, M., Bergsland, N., Weinstock-Guttman, B., Butzkueven, H., Kalincik, T., Desmond, P., Gaillard, F., Van Pesch, V., Ozakbas, S., Rojas, J., Wang, C., Kyle, K., et al (2021). Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study. NeuroImage: Clinical, 32, 102802. [More Information]
• Sesel, A., Sharpe, L., Beadnall, H., Barnett, M., Szabo, M., Naismith, S. (2021). Development of a web-based mindfulness program for people with multiple sclerosis: Qualitative co-design study. Journal of Medical Internet Research, 23(3), e19309. [More Information]
• Klistorner, S., Barnett, M., Wasserthal, J., Yiannikas, C., Barton, J., Parratt, J., You, Y., Graham, S., Klistorner, A. (2021). Differentiating axonal loss and demyelination in chronic MS lesions: A novel approach using single streamline diffusivity analysis. PloS One, 16, e0244766. [More Information]
• Le, M., Malpas, C., Sharmin, S., Horáková, D., Havrdova, E., Trojano, M., Izquierdo, G., Eichau, S., Ozakbas, S., Lugaresi, A., Barnett, M., et al (2021). Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. Multiple Sclerosis Journal, 27(5), 755-766. [More Information]
• Nakashima, I., Viswanathan, S., Wang, K., Shang, S., Miller, L., Yountz, M., Wingerchuk, D., Pittock, S., Levy, M., Berthele, A., Barnett, M., et al (2021). Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: A subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension. Multiple Sclerosis and Related Disorders, 50, 102849. [More Information]
• Kalincik, T., Diouf, I., Sharmin, S., Malpas, C., Spelman, T., Horakova, D., Havrdova, E., Trojano, M., Izquierdo, G., Lugaresi, A., Barnett, M., et al (2021). Effect of Disease Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. Neurology, 96(5), e783-e797. [More Information]
• Schweitzer, F., Laurent, S., Fink, G., Barnett, M., Hartung, H., Warnke, C. (2021). Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis. Journal of Neurology, 268(7), 2379-2389. [More Information]
• Maltby, V., Lea, R., Monif, M., Fabis-Pedrini, M., Buzzard, K., Kalincik, T., Kermode, A., Taylor, B., Hodgkinson, S., McCombe, P., Barnett, M., et al (2021). Efficacy of Cladribine Tablets as a Treatment for People with Multiple Sclerosis: Protocol for the CLOBAS Study (Cladribine, a Multicenter, Long-Term Efficacy and Biomarker Australian Study). JMIR Research Protocols, 10(10), e24969. [More Information]
• Klistorner, S., Barnett, M., Yiannikas, C., Barton, J., Parratt, J., You, Y., Graham, S., Klistorner, A. (2021). Expansion of chronic lesions is linked to disease progression in relapsing–remitting multiple sclerosis patients. Multiple Sclerosis Journal, 27(10), 1533-1542. [More Information]
• You, Y., Barnett, M., Yiannikas, C., Parratt, J., Matthews, J., Graham, S., Klistorner, A. (2021). Interferon-β Is Less Effective Than Other Drugs in Controlling the Rate of Retinal Ganglion Cell Loss in MS. Neurology: Neuroimmunology and Neuroinflammation, 8(3). [More Information]
• Klistorner, A., Triplett, J., Barnett, M., Yiannikas, C., Barton, J., Parratt, J., You, Y., Graham, S. (2021). Latency of Multifocal Visual Evoked Potential in Multiple Sclerosis: A Visual Pathway Biomarker for Clinical Trials of Remyelinating Therapies. Journal of Clinical Neurophysiology, 38(3), 186-191. [More Information]
• Tang, Z., Cabezas Grebol, M., Liu, D., Barnett, M., Cai, W., Wang, C. (2021). LG-Net: Lesion Gate Network for Multiple Sclerosis Lesion Inpainting. 24th International Conference on Medical Image Computing and Computer Assisted Intervention (MICCAI 2021), Cham: Springer Nature. [More Information]
• Wang, C., Barton, J., Kyle, K., Ly, L., Barnett, Y., Hartung, H., Reddel, S., Beadnall, H., Taha, M., Klistorner, A., Barnett, M. (2021). Multiple sclerosis: Structural and functional integrity of the visual system following alemtuzumab therapy. Journal of Neurology, Neurosurgery and Psychiatry, 92(12), 1319-1324. [More Information]
• Yeh, W., Widyastuti, P., van der Walt, A., Stankovich, J., Havrdova, E., Horakova, D., Vodehnalova, K., Ozakbas, S., Eichau, S., Duquette, P., Barnett, M., et al (2021). Natalizumab, Fingolimod and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis. Neurology, 96(24), e2989-e3002. [More Information]
• Nathani, D., Spies, J., Barnett, M., Pollard, J., Wang, M., Sommer, C., Kiernan, M. (2021). Nerve biopsy: Current indications and decision tools. Muscle and Nerve, 64(2), 125-139. [More Information]
• Rinaldi, S., Davies, A., Fehmi, J., Beadnall, H., Wang, J., Hardy, T., Barnett, M., Broadley, S., Waters, P., Reddel, S., Brilot-Turville, F., Dale, R., Ramanathan, S., et al (2021). Overlapping central and peripheral nervous system syndromes in MOG antibody-associated disorders. Neurology: Neuroimmunology and Neuroinflammation, 8(1). [More Information]
• Mate, S., Soutter, M., Hackett, D., Barnett, M., Fiatarone Singh, M., Sinan, J. (2021). Pilot Study of Enhancing Cardiorespiratory Exercise Response in People With Advanced Multiple Sclerosis With Hybrid Functional Electrical Stimulation. Archives of Physical Medicine and Rehabilitation, 102(12), 2385-2392. [More Information]
• Lizak, N., Hodgkinson, S., Butler, E., Lechner-Scott, J., Slee, M., McCombe, P., Shaw, C., Skibina, O., Vucic, S., Shuey, N., Barnett, M., et al (2021). Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy. Multiple Sclerosis Journal, 27(3), 465-474. [More Information]
• Klistorner, A., Barnett, M. (2021). Remyelination Trials: Are We Expecting the Unexpected? Neurology: Neuroimmunology and Neuroinflammation, 8(6), e1066. [More Information]
• Graf, J., Mares, J., Barnett, M., Aktas, O., Albrecht, P., Zamvil, S., Hartung, H. (2021). Targeting B Cells to Modify MS, NMOSD, and MOGAD: Part 1. Neurology: Neuroimmunology and Neuroinflammation, 8(1), 1-12. [More Information]
• Graf, J., Mares, J., Barnett, M., Aktas, O., Albrecht, P., Zamvil, S., Hartung, H. (2021). Targeting B cells to modify MS, NMOSD, and MOGAD: Part 2. Neurology: Neuroimmunology and Neuroinflammation, 8(1), 1-8. [More Information]
• Monschein, T., Hartung, H., Zrzavy, T., Barnett, M., Boxberger, N., Berger, T., Chataway, J., Bar-Or, A., Rommer, P., Zettl, U. (2021). Vaccination and multiple sclerosis in the era of the COVID-19 pandemic. Journal of Neurology, Neurosurgery and Psychiatry, 92(10), 1033-1043. [More Information]

2020

• Hartung, H., Mares, J., Barnett, M. (2020). Alemtuzumab: Rare serious adverse events of a high-efficacy drug. Multiple Sclerosis Journal, 26(6), 737-740. [More Information]
• You, Y., Barnett, M., Yiannikas, K., Parratt, J., Matthews, J., Graham, S., Klistorner, A. (2020). Chronic demyelination exacerbates neuroaxonal loss in patients with MS with unilateral optic neuritis. Neurology: Neuroimmunology and Neuroinflammation, 7(3), 1-10. [More Information]
• Fernández, O., Izquierdo, G., Aguera, E., Ramo, C., Hernandez, M., Silva, D., Walker, R., Butzkueven, H., Wang, C., Barnett, M. (2020). Comparison of first-line and second-line use of fingolimod in relapsing MS: The open-label EARLIMS study. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 6(3), 1-11. [More Information]
• Tea, F., Pilli, D., Ramanathan, S., Lopez, J., Merheb, V., Lee, F., Zou, A., Liyanage, G., Bassett, C., Thomsen, S., Reddel, S., Barnett, M., Brown, D., Dale, R., Brilot-Turville, F. (2020). Effects of the Positive Threshold and Data Analysis on Human MOG Antibody Detection by Live Flow Cytometry. Frontiers in Immunology, 11, 119. [More Information]
• Wang, D., Wang, C., Masters, L., Barnett, M. (2020). Masked Multi-Task Network for Case-Level Intracranial Hemorrhage Classification in Brain CT Volumes. 23rd International Conference on Medical Image Computing and Computer Assisted Intervention (MICCAI 2020), Cham: Springer. [More Information]
• Barnett, Y., Garber, J., Barnett, M. (2020). MRI biomarkers of disease progression in multiple sclerosis: Old dog, new tricks? Quantitative Imaging in Medicine and Surgery, 10(2), 527-532. [More Information]
• Xiong, H., Wang, C., Barnett, M., Wang, C. (2020). Multiple Sclerosis Lesion Filling Using a Non-lesion Attention Based Convolutional Network. 27th International Conference on Neural Information Processing (ICONIP 2020), Cham: Springer. [More Information]
• Garber, J., Beadnall, H., Barnett, M. (2020). Multiple sclerosis the role of the GP in diagnosis and lifetime care. Medicine Today, 21(12), 14-25.
• Forster, M., Weyers, V., Kury, P., Barnett, M., Hartung, H., Kremer, D. (2020). Neurological manifestations of severe acute respiratory syndrome coronavirus 2-a controversy 'gone viral'. Brain Communications, 2(2), fcaa149. [More Information]
• Ghadiri, M., Rezk, A., Li, R., Evans, A., Giacomini, P., Barnett, M., Antel, J., Bar-Or, A. (2020). Pre-treatment T-cell subsets associate with fingolimod treatment responsiveness in multiple sclerosis. Scientific Reports, 10(1), 356. [More Information]
• Trewin, B., Adelstein, S., Spies, J., Beadnall, H., Barton, J., Ho, N., Gallagher, K., Barnett, M. (2020). Precision therapy for neuromyelitis optica spectrum disorder: A retrospective analysis of the use of class-switched memory B-cells for individualised rituximab dosing schedules. Multiple Sclerosis and Related Disorders, 43, 1-4. [More Information]
• Tu, S., Wang, C., Menke, R., Talbot, K., Barnett, M., Kiernan, M., Turner, M. (2020). Regional callosal integrity and bilaterality of limb weakness in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 21(5-6), 396-402. [More Information]
• Khalilidehkordi, E., Clarke, L., Arnett, S., Bukhari, W., Jimenez Sanchez, S., O'Gorman, C., Sun, J., Prain, K., Woodhall, M., Silvestrini, R., Dale, R., Fulcher, D., Hawke, S., Heard, R., Lin, M., Pollard, J., Reddel, S., Spies, J., Vucic, S., Barnett, M., Parratt, J., et al (2020). Relapse Patterns in NMOSD: Evidence for Earlier Occurrence of Optic Neuritis and Possible Seasonal Variation. Frontiers in Neurology, 11, 1-8. [More Information]
• Fambiatos, A., Jokubaitis, V., Horakova, D., Kubala Havrdova, E., Trojano, M., Prat, A., Girard, M., Duquette, P., Lugaresi, A., Izquierdo, G., Barnett, M., et al (2020). Risk of secondary progressive multiple sclerosis: A longitudinal study. Multiple Sclerosis Journal, 26(1), 79-90. [More Information]
• Ebrahimkhani, S., Beadnall, H., Wang, C., Suter, C., Barnett, M., Buckland, M., Vafaee, F. (2020). Serum Exosome MicroRNAs Predict Multiple Sclerosis Disease Activity after Fingolimod Treatment. Molecular Neurobiology, 57(2), 1245-1258. [More Information]
• Bukhari, W., Clarke, L., O'Gorman, C., Khalilidehkordi, E., Arnett, S., Prain, K., Woodhall, M., Silvestrini, R., Bundell, C., Ramanathan, S., Dale, R., Fulcher, D., Hawke, S., Heard, R., Pollard, J., Brilot-Turville, F., Barnett, M., Spies, J., et al (2020). The clinical profile of NMOSD in Australia and New Zealand. Journal of Neurology, 267(5), 1431-1443. [More Information]
• Yam, C., Merlo, D., Stankovich, J., Darby, D., Gresle, M., Kalincik, T., Kilpatrick, T., Lechner-Scott, J., Taylor, B., Barnett, M., et al (2020). The MSReactor computerized cognitive battery correlates with the processing speed test in relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 43, 102212. [More Information]
• Hardy, T., Taylor, R., Qiu, J., O’Brien, B., Gopinath, S., Trewin, B., Spring, P., Shaffi, M., Bolitho, S., Garsia, R., Ip, J., Chen, L., Beadnall, H., Barnett, M., Parratt, J., Watson, J., Reddel, S., et al (2020). The neuro-otology of Susac syndrome. Journal of Neurology, 267(12), 3711-3722. [More Information]

2019

• Schweitzer, F., Laurent, S., Fink, G., Barnett, M., Reddel, S., Hartung, H., Warnke, C. (2019). Age and the risks of high-efficacy disease modifying drugs in multiple sclerosis. Current Opinion In Neurology, 32(3), 305-312. [More Information]
• Prain, K., Woodhall, M., Vincent, A., Ramanathan, S., Barnett, M., Bundell, C., Parratt, J., Silvestrini, R., Bukhari, W., Brilot-Turville, F., et al (2019). AQP4 Antibody Assay Sensitivity Comparison in the Era of the 2015 Diagnostic Criteria for NMOSD. Frontiers in Neurology, 10, 1-7. [More Information]
• Gross, C., Meyer, C., Bhatia, U., Yshii, L., Kleffner, I., Bauer, J., Troscher, A., Schulte-Mecklenbeck, A., Herich, S., Schneider-Hohendorf, T., Parratt, J., Barnett, M., Buckland, M., Hardy, T., Reddel, S., Wiendl, H., et al (2019). CD8+ T cell-mediated endotheliopathy is a targetable mechanism of neuro-inflammation in Susac syndrome. Nature Communications, 10(1), 1-19. [More Information]
• Tea, F., Lopez, J., Ramanathan, S., Merheb, V., Lee, F., Zou, A., Pilli, D., Patrick, E., van der Walt, A., Monif, M., Tantsis, E., Fraser, C., Reddel, S., Barnett, M., Brown, D., Dale, R., Brilot-Turville, F., et al (2019). Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination. Acta Neuropathologica Communications, 7(1), 1-22. [More Information]
• Beadnall, H., Wang, C., Van Hecke, W., Ribbens, A., Billiet, T., Barnett, M. (2019). Comparing longitudinal brain atrophy measurement techniques in a real-world multiple sclerosis clinical practice cohort: towards clinical integration? Therapeutic Advances in Neurological Disorders, 12, 1-20. [More Information]
• Lampit, A., Heine, J., Finke, C., Barnett, M., Valenzuela, M., Wolf, A., Leung, I., Hill, N. (2019). Computerized Cognitive Training in Multiple Sclerosis: A Systematic Review and Meta-analysis. Neurorehabilitation and Neural Repair, 33(9), 695-706. [More Information]
• Garg, N., Park, S., Howells, J., Vucic, S., Yiannikas, K., Mathey, E., Nguyen, T., Noto, Y., Barnett, M., Pollard, J., Kiernan, M. (2019). Conduction block in immune-mediated neuropathy: paranodopathy versus axonopathy. European Journal of Neurology, 26(8), 1121-1129. [More Information]
• Chaseling, G., Allen, D., Vucic, S., Barnett, M., Frohman, E., Davis, S., Jay, O. (2019). Core temperature is not elevated at rest in people with relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 29, 62-67. [More Information]
• You, Y., Joseph, C., Wang, C., Gupta, V., Liu, S., Yiannikas, C., Chua, B., Chitranshi, N., Shen, T., Dheer, Y., Invernizzi, A., Barnett, M., Klistorner, A., et al (2019). Demyelination precedes axonal loss in the transneuronal spread of human neurodegenerative disease. Brain, 142(2), 426-442. [More Information]
• Hartung, H., Graf, J., Aktas, O., Mares, J., Barnett, M. (2019). Diagnosis of multiple sclerosis: revisions of the McDonald criteria 2017 - continuity and change. Current Opinion In Neurology, 32, 327-337. [More Information]
• Shen, T., You, Y., Arunachalam, S., Fontes, A., Liu, S., Gupta, V., Parratt, J., Wang, C., Barnett, M., Barton, J., Zhu, L., Fraser, C., Graham, S., Klistorner, A., et al (2019). Differing Structural and Functional Patterns of Optic Nerve Damage in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder. Ophthalmology, 126(3), 445-453. [More Information]
• You, Y., Zhu, L., Zhang, T., Shen, T., Fontes, A., Yiannikas, C., Parratt, J., Barton, J., Schulz, A., Gupta, V., Barnett, M., Fraser, C., Gillies, M., Graham, S., Klistorner, A. (2019). Evidence of Muller Glial Dysfunction in Patients with Aquaporin-4 Immunoglobulin G-Positive Neuromyelitis Optica Spectrum Disorder. Ophthalmology, 126(6), 801-810. [More Information]
• Rigney, L., Triplett, J., Hardy, T., Barnett, Y., Hayes, M., Barnett, M., Reddel, S. (2019). Forearm predominant para-infectious myositis. Muscle and Nerve, 59(2), E7-E10. [More Information]
• Wang, C., Barnett, M., Barnett, Y. (2019). Imaging the multiple sclerosis lesion: insights into pathogenesis, progression and repair. Current Opinion In Neurology, 32(3), 338-345. [More Information]
• Triplett, J., Buzzard, K., Lubomski, M., Riminton, S., Barnett, M., Welgampola, M., Halmagyi, G., Nguyen, M., Landau, K., Lee, A., Fraser, C., Reddel, S., Hardy, T., et al (2019). Immune-mediated conditions affecting the brain, eye and ear (BEE syndromes). Journal of Neurology, Neurosurgery and Psychiatry, 90(8), 882-894. [More Information]
• Nguyen, A., Havrdova, E., Horakova, D., Izquierdo, G., Kalincik, T., van der Walt, A., Terzi, M., Alroughani, R., Duquette, P., Girard, M., Barnett, M., Vucic, S., et al (2019). Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. Multiple Sclerosis and Related Disorders, 28, 235-243. [More Information]
• Silsby, M., Sanchez, P., Spies, J., Firth, J., Barton, J., Beadnall, H., Barnett, M., Reddel, S., Hardy, T. (2019). Investigation of tumefactive demyelination is associated with higher economic burden and more adverse events compared with conventional multiple sclerosis. Multiple Sclerosis and Related Disorders, 35, 104-107. [More Information]
• Wang, C., Barnett, M., Yiannikas, C., Barton, J., Parratt, J., You, Y., Graham, S., Klistorner, A. (2019). Lesion activity and chronic demyelination are the major determinants of brain atrophy in MS. Neurology: Neuroimmunology and Neuroinflammation, 6(5), 1-9. [More Information]
• Moore, J., Massey, J., Ford, C., Khoo, M., Zaunders, J., Hendrawan, K., Barnett, Y., Barnett, M., Kyle, K., Zivadinov, R., et al (2019). Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 90(5), 514-521. [More Information]
• Klotz, L., Havla, J., Schwab, N., Hohlfeld, R., Barnett, M., Reddel, S., Wiendl, H. (2019). Risks and risk management in modern multiple sclerosis immunotherapeutic treatment. Therapeutic Advances in Neurological Disorders, 12, 1-31. [More Information]
• Dwyer, M., Bergsland, N., Ramasamy, D., Weinstock-Guttman, B., Barnett, M., Wang, C., Tomic, D., Silva, D., Zivadinov, R. (2019). Salient Central Lesion Volume: A Standardized Novel Fully Automated Proxy for Brain FLAIR Lesion Volume in Multiple Sclerosis. Journal of Neuroimaging, 29(5), 615-623. [More Information]
• Reddel, S., Barnett, M., Riminton, S., Dugal, T., Buzzard, K., Wang, C., Fitzgerald, F., Beadnall, H., Erickson, D., Gahan, D., et al (2019). Successful implementation of an automated electronic support system for patient safety monitoring: The alemtuzumab in multiple sclerosis safety systems (AMS3) study. Multiple Sclerosis Journal, 25(8), 1124-1131. [More Information]
• Barton, J., Garber, J., Klistorner, A., Barnett, M. (2019). The electrophysiological assessment of visual function in Multiple Sclerosis. Clinical Neurophysiology Practice, 4, 90-96. [More Information]
• Sesel, A., Sharpe, L., Beadnall, H., Barnett, M., Szabo, M., Naismith, S. (2019). The evaluation of an online mindfulness program for people with multiple sclerosis: study protocol. BMC Neurology, 19(1), 1-8. [More Information]
• Law, L., Riminton, D., Nguyen, M., Barnett, M., Reddel, S., Hardy, T. (2019). The spectrum of immune-mediated and inflammatory lesions of the brainstem: Clues to diagnosis. Neurology, 93(9), 390-405. [More Information]
• Nathani, D., Barnett, M., Spies, J., Pollard, J., Wang, M., Kiernan, M. (2019). Vasculitic neuropathy: Comparison of clinical predictors with histopathological outcome. Muscle and Nerve, 59(6), 643-649. [More Information]

2018

• Tang, Z., Wang, C., Hoang, P., Liu, S., Cai, W., Soligo, D., Oliver, R., Barnett, M., Fornusek, C. (2018). Automatic segmentation of thigh muscle in longitudinal 3D T1-weighted magnetic resonance (MR) images. Medical Image Computing and Computer-Assisted Intervention (MICCAI 2018) - First International Data Driven Treatment Response Assessment Workshop (DATRA 2018) and Third International Preterm, Perinatal, and Paediatric Image Analysis Workshop (PIPPI 2018), Cham: Springer Nature. [More Information]
• Kalincik, T., Jokubaitis, V., Spelman, T., Horakova, D., Havrdova, E., Trojano, M., Lechner-Scott, J., Lugaresi, A., Prat, A., Girard, M., et al (2018). Cladribine versus fingolimod, natalizumab and interferon beta for multiple sclerosis. Multiple Sclerosis Journal, 24(12), 1617-1626. [More Information]
• Ramanathan, S., Mohammad, S., Tantsis, E., Nguyen, T., Merheb, V., Fung, V., White, O., Broadley, S., Lechner-Scott, J., Vucic, S., Henderson, A., Barnett, M., Reddel, S., Brilot-Turville, F., Dale, R. (2018). Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. Journal of Neurology, Neurosurgery and Psychiatry, 89(2), 127-137. [More Information]
• Chaseling, G., Filingeri, D., Barnett, M., Hoang, P., Davis, S., Jay, O. (2018). Cold Water Ingestion Improves Exercise Tolerance of Heat-Sensitive People with MS. Medicine and Science in Sports and Exercise, 50(4), 643-648. [More Information]
• Ebrahimkhani, S., Vafaee, F., Hallal, S., Wei, H., Lee, M., Young, P., Satgunaseelan, L., Beadnall, H., Barnett, M., Shivalingam, B., Buckland, M., Alexander, K., et al (2018). Deep sequencing of circulating exosomal microRNA allows non-invasive glioblastoma diagnosis. n p j Precision Oncology, 2, 1-9. [More Information]
• Klistorner, A., Wang, C., Yiannikas, C., Parratt, J., Barton, J., You, Y., Graham, S., Barnett, M. (2018). Diffusivity in the core of chronic multiple sclerosis lesions. PloS One, 13(4), 1-20. [More Information]
• Klistorner, A., Wang, C., Yiannikas, C., Parratt, J., Dwyer, M., Barton, J., Graham, S., You, Y., Liu, S., Barnett, M. (2018). Evidence of progressive tissue loss in the core of chronic MS lesions: A longitudinal DTI study. NeuroImage: Clinical, 17, 1028-1035. [More Information]
• Fragoso, Y., Spelman, T., Boz, C., Alroughani, R., Lugaresi, A., Vucic, S., Butzkueven, H., Terzi, M., Havrdova, E., Barnett, M., et al (2018). Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod. Multiple Sclerosis and Related Disorders, 19, 105-108. [More Information]
• Zhang, C., Song, Y., Liu, S., Lill, S., Wang, C., Tang, Z., You, Y., Gao, Y., Klistorner, A., Barnett, M., Cai, W. (2018). MS-GAN: GAN-Based Semantic Segmentation of Multiple Sclerosis Lesions in Brain Magnetic Resonance Imaging. 2018 International Conference on Digital Image Computing: Techniques and Applications (DICTA 2018), Piscataway: Institute of Electrical and Electronics Engineers (IEEE). [More Information]
• Triplett, J., Yiannikas, C., Barnett, M., Parratt, J., Barton, J., Graham, S., You, Y., Klistorner, A. (2018). Pathophysiological basis of low contrast visual acuity loss in multiple sclerosis. Annals of Clinical and Translational Neurology, 5(12), 1505-1512. [More Information]
• You, Y., Graham, E., Shen, T., Yiannikas, C., Parratt, J., Gupta, V., Barton, J., Dwyer, M., Barnett, M., Fraser, C., Klistorner, A., et al (2018). Progressive inner nuclear layer dysfunction in non-optic neuritis eyes in MS. Neurology: Neuroimmunology and Neuroinflammation, 5(1), 1-9. [More Information]
• Fragoso, Y., Brooks, J., Spelman, T., Boz, C., Alroughani, R., Lugaresi, A., Vucic, S., Butzkueven, H., Terzi, M., Barnett, M., et al (2018). Reply to: Comment on YD Fragoso et al: Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod" [Mult Scler Relat Disord (2017)]". Multiple Sclerosis and Related Disorders, 22, 166. [More Information]
• Min, M., Spelman, T., Lugaresi, A., Boz, C., Spitaleri, D., Pucci, E., Grand’Maison, F., Granella, F., Barnett, M., Vucic, S., et al (2018). Silent lesions on MRI imaging - Shifting goal posts for treatment decisions in multiple sclerosis. Multiple Sclerosis Journal, 24(12), 1569-1577. [More Information]
• Christogianni, A., Bibb, R., Davis, S., Jay, O., Barnett, M., Evangelou, N., Filingeri, D. (2018). Temperature sensitivity in multiple sclerosis: An overview of its impact on sensory and cognitive symptoms. Temperature, 5(3), 208-223. [More Information]
• Lu, G., Beadnall, H., Barton, J., Hardy, T., Wang, C., Barnett, M. (2018). The evolution of No Evidence of Disease Activity" in multiple sclerosis". Multiple Sclerosis and Related Disorders, 20, 231-238. [More Information]
• Garber, J., Barnett, M. (2018). We should focus more on finding therapeutic targets for the non-inflammatory damage in MS - Yes. Multiple Sclerosis Journal, 24(10), 1272-1274. [More Information]
• Wang, C., Klistorner, A., Ly, L., Barnett, M. (2018). White matter tract-specific quantitative analysis in multiple sclerosis: Comparison of optic radiation reconstruction techniques. PloS One, 13(1), 1-19. [More Information]

2017

• Filingeri, D., Chaseling, G., Hoang, P., Barnett, M., Davis, S., Jay, O. (2017). Afferent thermosensory function in relapsing-remitting Multiple Sclerosis following exercise-induced increases in body temperature. Experimental Physiology, 102(8), 887-893. [More Information]
• Mathey, E., Garg, N., Park, S., Nguyen, T., Baker, S., Yuki, N., Yiannikas, K., Lin, C., Spies, J., Ghaoui, R., Barnett, M., Vucic, S., Pollard, J., Kiernan, M. (2017). Autoantibody responses to nodal and paranodal antigens in chronic inflammatory neuropathies. Journal of Neuroimmunology, 309, 41-46. [More Information]
• Stewart, T., Spelman, T., Havrdova, E., Horakova, D., Trojano, M., Izquierdo, G., Duquette, P., Girard, M., Prat, A., Vucic, S., Barnett, M., et al (2017). Contribution of different relapse phenotypes to disability in multiple sclerosis. Multiple Sclerosis Journal, 23(2), 266-276. [More Information]
• De Stefano, N., Silva, D., Barnett, M. (2017). Effect of Fingolimod on Brain Volume Loss in Patients with Multiple Sclerosis. CNS Drugs, 31(4), 289-305. [More Information]
• Fornusek, C., Hoang, P., Barnett, M., Oliver, R., Burns, J. (2017). Effect of neuromuscular electrical stimulation cycling on thigh muscle mass and strength in persons with advanced multiple sclerosis. Journal of the Neurological Sciences, 381, 248-248.
• Ebrahimkhani, S., Vafaee, F., Young, P., Hur, S., Hawke, S., Devenney, E., Beadnall, H., Barnett, M., Suter, C., Buckland, M. (2017). Exosomal microRNA signatures in multiple sclerosis reflect disease status. Scientific Reports, 7(1), 1-10. [More Information]
• Bukhari, W., Prain, K., Waters, P., Woodhall, M., O'Gorman, C., Clarke, L., Silvestrini, R., Bundell, C., Abernethy, D., Dale, R., Fulcher, D., Hawke, S., Heard, R., Lin, M., Pollard, J., Reddel, S., Spies, J., Vucic, S., Barnett, M., et al (2017). Incidence and prevalence of NMOSD in Australia and New Zealand. Journal of Neurology, Neurosurgery and Psychiatry, 88(8), 632-638. [More Information]
• Dale, R., Barnett, M., Kiernan, M. (2017). Maternal autoimmunity: Risk of neurodevelopmental and neuropsychiatric outcomes. Journal of Neurology, Neurosurgery and Psychiatry, 88(9), 713-714. [More Information]
• Egger, C., Opfer, R., Wang, C., Kepp, T., Sormani, M., Spies, L., Barnett, M., Schippling, S. (2017). MRI FLAIR lesion segmentation in multiple sclerosis: Does automated segmentation hold up with manual annotation? NeuroImage: Clinical, 13, 264-270. [More Information]
• Klistorner, A., Graham, E., Yiannikas, C., Barnett, M., Parratt, J., Garrick, R., Wang, C., You, Y., Graham, S. (2017). Progression of retinal ganglion cell loss in multiple sclerosis is associated with new lesions in the optic radiations. European Journal of Neurology, 24(11), 1392-1398. [More Information]
• Kalincik, T., Manouchehrinia, A., Sobisek, L., Jokubaitis, V., Spelman, T., Horakova, D., Havrdova, E., Trojano, M., Izquierdo, G., Vucic, S., Barnett, M., et al (2017). Towards personalized therapy for multiple sclerosis: Prediction of individual treatment response. Brain, 140(9), 2426-2443. [More Information]
• Kalincik, T., Brown, J., Robertson, N., Willis, M., Scolding, N., Rice, C., Wilkins, A., Pearson, O., Barnett, M., Vucic, S., et al (2017). Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. The Lancet Neurology, 16(4), 271-281. [More Information]
• Barton, J., Hardy, T., Riminton, D., Reddel, S., Barnett, Y., Coles, A., Barnett, M. (2017). Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab. Neurology, 88(10), 1004-1006. [More Information]
• Aw, S., Chen, L., Todd, M., Barnett, M., Halmagyi, G. (2017). Vestibulo-ocular reflex deficits with medial longitudinal fasciculus lesions. Journal of Neurology, 264(10), 2119-2129. [More Information]

2016

• Garg, N., Yuki, N., Park, S., Barnett, M., Kiernan, M. (2016). Acute bulbar, neck and limb weakness with monospecific anti-GT1a antibody: A rare localized subtype of Guillain-Barre sydnrome. Muscle and Nerve, 53(1), 143-146. [More Information]
• Hardy, T., Reddel, S., Barnett, M., Palace, J., Lucchinetti, C., Weinshenker, B. (2016). Atypical inflammatory demyelinating syndromes of the CNS. The Lancet Neurology, 15(9), 967-981. [More Information]
• Wang, C., Beadnall, H., Hatton, S., Bader, G., Tomic, D., Silva, D., Barnett, M. (2016). Automated brain volumetrics in multiple sclerosis: a step closer to clinical application. Journal of Neurology, Neurosurgery and Psychiatry, 87(7), 754-757. [More Information]
• Barnett, M., Mathey, E., Kiernan, M., Pollard, J. (2016). Axon damage in central nervous system and peripheral nervous system inflammatory demyelinating diseases: common and divergent pathways of dysfunction and tissue damage. Current Opinion In Neurology, 29(3), 213-221. [More Information]
• Zivadinov, R., Jakimovski, D., Gandhi, S., Ahmed, R., Dwyer, M., Horakova, D., Weinstock-Guttman, B., Benedict, R., Vaneckova, M., Barnett, M., et al (2016). Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine. Expert Review of Neurotherapeutics, 16(7), 777-793. [More Information]
• Chaseling, G., Filingeri, D., Hoang, P., Barnett, M., Davis, S., Jay, O. (2016). Cold fluid ingestion extends exercise capacity of heat-sensitive individuals with Multiple Sclerosis in a warm environment. Experimental Biology Meeting 2016, Bethesda, MD: Federation of American Societies for Experimental Biology.
• Lorscheider, J., Buzzard, K., Jokubaitis, V., Spelman, T., Havrdova, E., Horakova, D., Trojano, M., Izquierdo, G., Girard, M., Vucic, S., Barnett, M., et al (2016). Defining secondary progressive multiple sclerosis. Brain, 139(PT 9), 2395-2405. [More Information]
• Klistorner, A., Wang, C., Fofanova, V., Barnett, M., Yiannikas, C., Parratt, J., You, Y., Graham, S. (2016). Diffusivity in multiple sclerosis lesions: At the cutting edge? NeuroImage: Clinical, 12, 219-226. [More Information]
• Kister, I., Spelman, T., Alroughani, R., Lechner-Scott, J., Duquette, P., Grand' Maison, F., Slee, M., Lugaresi, A., Barnett, M., Grammond, P., et al (2016). Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: A propensity score-matched study. Journal of Neurology, Neurosurgery and Psychiatry, 87(10), 1133-1137. [More Information]
• Filingeri, D., Chaseling, G., Hoang, P., Barnett, M., Davis, S., Jay, O. (2016). Effects of exercise-induced increases in body temperatures on local skin thermal sensitivity in Multiple Sclerosis patients. Experimental Biology Meeting 2016, Bethesda, MD: Federation of American Societies for Experimental Biology.
• Tao, C., Simpson, S., van der Mei, I., Blizzard, L., Havrdova, E., Horakova, D., Shaygannejad, V., Lugaresi, A., Izquierdo, G., Barnett, M., Vucic, S., et al (2016). Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 87(12), 1343-1349. [More Information]
• Barnett, M., McLeod, J., Hammond, S., Kurtzke, J. (2016). Migration and multiple sclerosis in immigrants from United Kingdom and Ireland to Australia: a reassessment III: risk of multiple sclerosis in UKI immigrants and Australian-born in Hobart, Tasmania. Journal of Neurology, 263(4), 792-798. [More Information]
• Kemp, S., Allan, R., Patanjali, N., Barnett, M., Jonker, B. (2016). Neurological deficit following stereotactic radiosurgery for trigeminal neuralgia. Journal of Clinical Neuroscience, 34, 229-231. [More Information]
• Zinger, A., Latham, S., Combes, V., Byrne, S., Barnett, M., Hawke, S., Grau, G. (2016). Plasma levels of endothelial and B-cell-derived microparticles are restored by fingolimod treatment in multiple sclerosis patients. Multiple Sclerosis Journal, 22(14), 1883-1887. [More Information]
• Klistorner, A., Wang, C., Yiannikas, C., Graham, S., Parratt, J., Barnett, M. (2016). Progressive injury in chronic multiple sclerosis lesions is gender-specific: A DTI study. PloS One, 11(2), 1-11. [More Information]
• Graham, E., You, Y., Yiannikas, C., Garrick, R., Parratt, J., Barnett, M., Klistorner, A. (2016). Progressive Loss of Retinal Ganglion Cells and Axons in Nonoptic Neuritis Eyes in Multiple Sclerosis: A Longitudinal Optical Coherence Tomography Study. Investigative Ophthalmology and Visual Science, 57(4), 2311-2317. [More Information]
• Ramanathan, S., Prelog, K., Barnes, E., Tantsis, E., Reddel, S., Henderson, A., Vucic, S., Gorman, M., Benson, L., Alper, G., Barnett, M., Parratt, J., Hardy, T., Merheb, V., Nosadini, M., Fung, V., Brilot-Turville, F., Dale, R., et al (2016). Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis. Multiple Sclerosis Journal, 22(4), 470-482. [More Information]
• Spelman, T., Mekhael, L., Burke, T., Butzkueven, H., Hodgkinson, S., Havrdova, E., Horakova, D., Duquette, P., Izquierdo, G., Grand' Maison, F., Barnett, M., Vucic, S., et al (2016). Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis. European Journal of Neurology, 23(4), 729-776. [More Information]
• Warrender-Sparkes, M., Spelman, T., Izquierdo, G., Trojano, M., Lugaresi, A., Grand'Maison, F., Havrdova, E., Horakova, D., Boz, C., Barnett, M., et al (2016). The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. Multiple Sclerosis Journal, 22(4), 520-532. [More Information]
• Jain, S., Ribbens, A., Sima, D., Cambron, M., De Keyser, J., Wang, C., Barnett, M., Van Huffel, S., Maes, F., Smeets, D. (2016). Two time point MS lesion segmentation in brain MRI: An expectation-maximization framework. Frontiers in Neuroscience, 10, 1-11. [More Information]
• Beadnall, H., Gill, A., Riminton, S., Barnett, M. (2016). Virus-related Merkel cell carcinoma complicating fingolimod treatment for multiple sclerosis. Neurology, 87(24), 2595-2597. [More Information]
• Hardy, T., Wang, C., Beadnall, H., Lagopoulos, J., Barnett, Y., Klistorner, A., Barnett, M. (2016). Wallerian Degeneration in the Corticospinal Tract Following Tumefactive Demyelination: Conventional and Advanced Magnetic Resonance Imaging. Canadian Journal of Neurological Sciences, 43(5), 726-727. [More Information]

2015

• Broadley, S., Barnett, M., Boggild, M., Brew, B., Butzkueven, H., Heard, R., Hodgkinson, S., Kermode, A., Lechner-Scott, J., Macdonell, R., Parratt, J., Reddel, S., Spies, J., Pollard, J., et al (2015). A new era in the treatment of multiple sclerosis. Medical Journal of Australia, 203(3), 139-141. [More Information]
• Gu, B., Field, J., Dutertre, S., Ou, A., Kilpatrick, T., Lechner-Scott, J., Scott, R., Lea, R., Taylor, B., Stankovich, J., et al (2015). A rare P2X7 variant Arg307Gln with absent pore formation function protects against neuroinflammation in multiple sclerosis. Human Molecular Genetics, 24(19), 5644-5654. [More Information]
• Wang, C., Paling, D., Chen, L., Hatton, S., Lagopoulos, J., Aw, S., Kiernan, M., Barnett, M. (2015). Axonal conduction in multiple sclerosis: A combined magnetic resonance imaging and electrophysiological study of the medial longitudinal fasciculus. Multiple Sclerosis Journal, 21(7), 905-915. [More Information]
• Hardy, T., Beadnall, H., Sutton, I., Mohamed, A., Buckland, M., Barnett, M. (2015). Balo's concentric sclerosis and tumefactive demyelination: A shared immunopathogenesis? Journal of the Neurological Sciences, 348(1-2), 279-281. [More Information]
• Hardy, T., O’Brien, B., Gerbis, N., Barnett, M., Reddel, S., Brewer, J., Herkes, G., Silberstein, P., Garsia, R., Watson, J., Gupta, R., Parratt, J., et al (2015). Brain histopathology in three cases of Susac's syndrome: Implications for lesion pathogenesis and treatment. Journal of Neurology, Neurosurgery and Psychiatry, 86(5), 582-584. [More Information]
• Mathey, E., Park, S., Hughes, R., Pollard, J., Armati, P., Barnett, M., Taylor, B., Dyck, J., Kiernan, M., Lin, C. (2015). Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. Journal of Neurology, Neurosurgery and Psychiatry, 86(9), 973-985. [More Information]
• Kalincik, T., Jokubaitis, V., Izquierdo, G., Duquette, P., Girard, M., Grammond, P., Lugaresi, A., Oreja-Guevara, C., Bergamaschi, R., Hupperts, R., Barnett, M., et al (2015). Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 21(9), 1159-1171. [More Information]
• Spelman, T., Kalincik, T., Zhang, A., Pellegrini, F., Wiendl, H., Kappos, L., Tsvetkova, L., Belachew, S., Hyde, R., Barnett, M., et al (2015). Comparative efficacy of switching to natalizumab in active multiple sclerosis. Annals of Clinical and Translational Neurology, 2(4), 373-387. [More Information]
• Klistorner, A., Vootakuru, N., Wang, C., Yiannikas, C., Graham, S., Parratt, J., Garrick, R., Levin, N., Masters, L., Lagopoulos, J., Barnett, M. (2015). Decoding diffusivity in multiple sclerosis: analysis of optic radiation lesional and non-lesional white matter. PloS One, 10(3), 1-23. [More Information]
• Kalincik, T., Cutter, G., Spelman, V., Jokubaitis, V., Havrdova, E., Horakova, D., Trojano, M., Izquierdo, G., Girard, M., Duquette, P., Barnett, M., et al (2015). Defining reliable disability outcomes in multiple sclerosis. Brain, 138(11), 3287-3298. [More Information]
• Buzzard, K., Reddel, S., Yiannikas, K., Riminton, S., Barnett, M., Hardy, T. (2015). Distinguishing Susac's syndrome from multiple sclerosis. Journal of Neurology, 262(7), 1613-1621. [More Information]
• Ribbons, K., McElduff, P., Boz, C., Trojano, M., Izquierdo, G., Duquette, P., Girard, M., Grand' Maison, F., Hupperts, R., Grammond, P., Barnett, M., et al (2015). Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS. PloS One, 10(6), 1-11. [More Information]
• Rojas, J., Patrucco, L., Trojano, M., Lugaresi, A., Izquierdo, G., Butzkueven, H., Jokubaitis, V., Duquette, P., Girard, M., Grand'Maison, F., et al (2015). Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase Registry. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 1. [More Information]
• Jokubaitis, V., Spelman, T., Kalincik, T., Izquierdo, G., Grand'Maison, F., Duquette, P., Girard, M., Lugaresi, A., Grammond, P., Hupperts, R., Barnett, M., et al (2015). Predictors of disability worsening in clinically isolated syndrome. Annals of Clinical and Translational Neurology, 2(5), 479-491. [More Information]
• Kalincik, T., Horakova, D., Spelman, T., Jokubaitis, V., Trojano, M., Lugaresi, A., Izquierdo, G., Rozsa, C., Grammond, P., Alroughani, R., Barnett, M., et al (2015). Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. Annals of Neurology, 77(3), 425-435. [More Information]
• Beadnall, H., Kuppanda, K., O'Connell, A., Hardy, T., Reddel, S., Barnett, M. (2015). Tablet-based screening improves continence management in multiple sclerosis. Annals of Clinical and Translational Neurology, 2(6), 679-687. [More Information]
• Garg, N., Reddel, S., Miller, D., Chataway, J., Riminton, S., Barnett, Y., Masters, L., Barnett, M., Hardy, T. (2015). The corpus callosum in the diagnosis of multiple sclerosis and other CNS demyelinating and inflammatory diseases. Journal of Neurology, Neurosurgery and Psychiatry, 86(12), 1374-1382. [More Information]

2014

• Ramanathan, S., Reddel, S., Henderson, A., Parratt, J., Barnett, M., Gatt, P., Merheb, V., Kumaran, R., Pathmanandavel, K., Sinmaz, N., Yiannikas, K., Vucic, S., Stewart, G., Booth, D., Dale, R., Brilot-Turville, F., et al (2014). Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurology: Neuroimmunology and Neuroinflammation, 1(4), 1-12. [More Information]
• Klistorner, A., Sriram, P., Vootakuru, N., Wang, C., Barnett, M., Garrick, R., Parratt, J., Levin, N., Raz, N., van der Walt, A., Masters, L., et al (2014). Axonal loss of retinal neurons in multiple sclerosis associated with optic radiation lesions. Neurology, 82(24), 2165-2172. [More Information]
• Cordina, R., Grieve, S., Barnett, M., Lagopoulos, J., Malitz, N., Celermajer, D. (2014). Brain volumetric, regional cortical thickness and radiographic findings in adults with cyanotic congenital heart disease. NeuroImage: Clinical, 4, 319-325. [More Information]
• Barnett, Y., Sutton, I., Ghadiri, M., Masters, L., Zivadinov, R., Barnett, M. (2014). Conventional and Advanced Imaging in Neuromyelitis Optica. American Journal Of Neuroradiology, 35(8), 1458-1466. [More Information]
• Malik, O., Donnelly, A., Barnett, M. (2014). Fast Facts: Multiple Sclerosis 3rd edition. Oxford: Health Press Limited.
• Jokubaitis, V., Li, V., Kalincik, T., Izquierdo, G., Hodgkinson, S., Alroughani, R., Lechner-Scott, J., Lugaresi, A., Duquette, P., Girard, M., Barnett, M., et al (2014). Fingolimod after natalizumab and the risk of short-term relapse. Neurology, 82(14), 1204-1211. [More Information]
• Alshowaeir, D., Yiannikas, C., Garrick, R., Parratt, J., Barnett, M., Graham, S., Klistorner, A. (2014). Latency of multifocal Visual Evoked Potentials in non-optic neuritis eyes of multiple sclerosis patients associated with optic radiation lesions. Investigative Ophthalmology and Visual Science, 55(6), 3758-3764. [More Information]
• Hughes, S., Spelman, T., Gray, O., Boz, C., Trojano, M., Lugaresi, A., Izquierdo, G., Duquette, P., Girard, M., Grand' Maison, F., Barnett, M., Vucic, S., et al (2014). Predictors and dynamics of postpartum relapses in women with multiple sclerosis. Multiple Sclerosis Journal, 20(6), 739-746. [More Information]
• Ghadiri, M., Buckland, M., Sutton, I., Al Jahdhami, S., Flanagan, S., Heard, R., Barnett, Y., Brennan, J., Barnett, M. (2014). Progressive Neuropsychiatric Symptoms and Motor Impairment. JAMA Neurology, 71(6), 794-798. [More Information]
• Sriram, P., Wang, C., Yiannikas, C., Garrick, R., Barnett, M., Parratt, J., Graham, S., Arvind Srinivasan, H., Klistorner, A. (2014). Relationship between optical coherence tomography and electrophysiology of the visual pathway in non-optic neuritis eyes of multiple sclerosis patients. PloS One, 9(8), 1-10. [More Information]
• Spelman, T., Gray, O., Trojano, M., Petersen, T., Izquierdo, G., Lugaresi, A., Hupperts, R., Bergamaschi, R., Duquette, P., Grammond, P., Barnett, M., Vucic, S., et al (2014). Seasonal variation of relapse rate in multiple sclerosis is latitude dependent. Annals of Neurology, 76(6), 880-890. [More Information]
• Parnell, G., Gatt, P., Krupa, M., Dorothee, N., McKay, F., Schibeci, S., Batten, M., Baranzini, S., Henderson, A., Barnett, M., Vucic, S., Stewart, G., Booth, D., et al (2014). The autoimmune disease-associated transcription factors EOMES and TBX21 are dysregulated in multiple sclerosis and define a molecular subtype of disease. Clinical Immunology, 151(1), 16-24. [More Information]
• Broadley, S., Barnett, M., Boggild, M., Brew, B., Butzkueven, H., Heard, R., Hodgkinson, S., Kermode, A., Lechner-Scott, J., Macdonell, R., Parratt, J., Reddel, S., Spies, J., Pollard, J., et al (2014). Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 1 Historical and established therapies. Journal of Clinical Neuroscience, 21(11), 1835-1846. [More Information]
• Broadley, S., Barnett, M., Boggild, M., Brew, B., Butzkueven, H., Heard, R., Hodgkinson, S., Kermode, A., Lechner-Scott, J., Macdonell, R., Parratt, J., Reddel, S., Spies, J., Pollard, J., et al (2014). Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 2 New and emerging therapies and their efficacy. Journal of Clinical Neuroscience, 21(11), 1847-1856. [More Information]
• Broadley, S., Barnett, M., Boggild, M., Brew, B., Butzkueven, H., Heard, R., Hodgkinson, S., Kermode, A., Lechner-Scott, J., Macdonell, R., Parratt, J., Reddel, S., Spies, J., Pollard, J., et al (2014). Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 3 Treatment practicalities and recommendations. Journal of Clinical Neuroscience, 21(11), 1857-1865. [More Information]

2013

• Klistorner, A., Garrick, R., Barnett, M., Graham, S., Arvind Srinivasan, H., Sriram, P., Yiannikas, C. (2013). Axonal loss in non-optic neuritis eyes of patients with multiple sclerosis linked to delayed visual evoked potential. Neurology, 80(3), 242-245. [More Information]
• Verheul, F., Smolders, J., Trojano, M., Lepore, V., Zwanikken, C., Amato, M., Grand'Maison, F., Butzkueven, H., Marrosu, M., Duquette, P., Barnett, M., et al (2013). Fluctuations of MS births and UV-light exposure. Acta Neurologica Scandinavica, 127(5), 301-308. [More Information]
• Lin, R., Charlesworth, J., Stankovich, J., Perreau, V., Brown, M., Taylor, B., Baxter, A., Kermode, A., Bahlo, M., Booth, D., Stewart, G., Barnett, M., Heard, R., et al (2013). Identity-by-Descent Mapping to Detect Rare Variants Conferring Susceptibility to Multiple Sclerosis. PloS One, 8(3), 1-8. [More Information]
• Kaushik, M., Wang, C., Barnett, M., Garrick, R., Parratt, J., Graham, S., Sriram, P., Yiannikas, C., Klistorner, A. (2013). Inner Nuclear Layer Thickening Is Inversley Proportional to Retinal Ganglion Cell Loss in Optic Neuritis. PloS One, 8(10), 1-8. [More Information]
• Kalinick, T., Spelman, T., Trojano, M., Duquette, P., Izquierdo, G., Grammond, P., Lugaresi, A., Hupperts, R., Cristiano, E., Van Pesch, V., Barnett, M., Vucic, S., et al (2013). Persistence on Therapy and Propensity Matched Outcome Comparison of Two Subcutaneous Interferon Beta 1a Dosages for Multiple Sclerosis. PloS One, 8(5), 1-9. [More Information]
• Kalincik, T., Vivek, V., Jokubaitis, V., Lechner-Scott, J., Trojano, M., Izquierdo, G., Lugaresi, A., Grand'Maison, F., Hupperts, R., Oreja-Guevara, C., Vucic, S., Barnett, M., et al (2013). Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. Brain, 136(12), 3609-3617. [More Information]
• Jokubaitis, V., Spelman, T., Lechner-Scott, J., Barnett, M., Shaw, C., Vucic, S., Liew, D., Butzkueven, H., Slee, M. (2013). The Australian Multiple Sclerosis (MS) immunotherapy study: a prospective, multicentre study of drug utilisation using the MSBase platform. PloS One, 8(3), 1-9. [More Information]
• Minagar, A., Barnett, M., Benedict, R., Pelletier, D., Pirko, I., Sahraian, M., Frohman, E., Zivadinov, R. (2013). The thalamus and multiple sclerosis: Modern views on pathologic, imaging, and clinical aspects. Neurology, 80(2), 210-219. [More Information]

2012

• Meyniel, C., Spelman, T., Jokubaitis, V., Trojano, M., Izquierdo, G., Grand'Maison, F., Oreja-Guevara, C., Boz, C., Lugaresi, A., Girard, M., Barnett, M., et al (2012). Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. PloS One, 7(6), 1-8. [More Information]
• Simon, N., Parratt, J., Barnett, M., Buckland, M., Gupta, R., Hayes, M., Masters, L., Reddel, S. (2012). Expanding the clinical, radiological and neuropathological phenotype of chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). Journal of Neurology, Neurosurgery and Psychiatry, 83(1), 15-22. [More Information]
• Bien, C., Vincent, A., Barnett, M., Becker, A., Blumcke, I., Graus, F., Jellinger, K., Reuss, D., Ribalta, T., Schlegel, J., et al (2012). Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain, 135(Pt 5), 1622-1638. [More Information]
• Chohan, G., Barnett, Y., Gibson, J., Reddel, S., Barnett, M. (2012). Langerhans cell histiocytosis with refractory central nervous system involvement responsive to infliximab. Journal of Neurology, Neurosurgery and Psychiatry, 83(5), 573-575. [More Information]
• Barnett, M., Prineas, J., Buckland, M., Parratt, J., Pollard, J. (2012). Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy. Multiple Sclerosis Journal, 18(1), 108-112. [More Information]
• Bukhari, W., Barnett, M., Prain, K., Broadley, S. (2012). Molecular Pathogenesis of Neuromyelitis Optica. International Journal of Molecular Sciences, 13(10), 12970-12993. [More Information]
• Barnett, M., Sutton, I. (2012). Neuromyelitis optica: not a multiple sclerosis variant. Current Opinion In Neurology, 25(3), 215-220. [More Information]
• Barnett, M., Hardy, T., Garsia, R., Halmagyi, G., Lewis, S., Harrisberg, B., Fulham, M. (2012). Response to Letter to the Editor: Susac's syndrome. Journal of the Neurological Sciences, 314(1-2), 183-183. [More Information]
• Hurelbrink, C., Barnett, Y., Buckland, M., Wilkinson, M., Leicester, J., Anderson, C., Brennan, J., Barnett, M. (2012). Revisiting cerebral thromboangiitis obliterans. Journal of the Neurological Sciences, 317(1-2), 141-145. [More Information]
• Hardy, T., Barnett, M., Nikpour (Mohamed), A., Garsia, R., Davies, L. (2012). Severe Bickerstaffs encephalitis treated with Rituximab: Serum and CSF GQ1b antibodies. Journal of Neuroimmunology, 251(1/2), 107-109. [More Information]
• Disanto, G., Morahan, J., Barnett, M., Giovannoni, G., Ramagopalan, S. (2012). The evidence for a role of B cells in multiple sclerosis. Neurology, 78(11), 823-832. [More Information]
• Lechner-Scott, J., Spencer, B., de Malmanche, T., Attia, J., Fitzgerald, M., Trojano, M., Francois, G., Gomez, J., Izquierdo, G., Duquette, P., Barnett, M., et al (2012). The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude. Multiple Sclerosis Journal, 18(7), 974-982. [More Information]
• Hughes, S., Spelman, T., Trojano, M., Lugaresi, A., Izquierdo, G., Grand'Maison, F., Duquette, P., Girard, M., Grammond, P., Oreja-Guevara, C., Barnett, M., et al (2012). The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry. Journal of Neurology, Neurosurgery and Psychiatry, 83(3), 305-310. [More Information]

2011

• Barnett, M., Chohan, G., Davies, L. (2011). Blurred vision and pain in the eye. Medical Journal of Australia, 195(6), 329-332. [More Information]
• Ly, L., Barnett, M., Zheng, Y., Gulati, T., Prineas, J., Crossett, B. (2011). Comprehensive Tissue Processing Strategy for Quantitative Proteomics of Formalin-fixed Multiple Sclerosis Lesions. Journal of Proteome Research, 10(10), 4855-4868. [More Information]
• Ahmed, R., Buckland, M., Davies, L., Halmagyi, G., Rogers, S., Oberste, M., Barnett, M. (2011). Enterovirus 71 meningoencephalitis complicating rituximab therapy. Journal of the Neurological Sciences, 305(1-2), 149-151. [More Information]
• Barnett, M., Barnett, Y., Burke, D., Willison, H. (2011). Spinal nerve root hypertrophy in chronic ataxic neuropathy with antiglycolipid IgM antibodies. Journal of Neurology, Neurosurgery and Psychiatry, 82(1), 97. [More Information]
• Hardy, T., Garsia, R., Halmagyi, G., Lewis, S., Harrisberg, B., Fulham, M., Barnett, M. (2011). Tumour necrosis factor (TNF) inhibitor therapy in Susac's syndrome. Journal of the Neurological Sciences, 302(1-2), 126-128. [More Information]

2010

• Henderson, A., Barnett, M., Parratt, J. (2010). Reply. Annals of Neurology, 68(5), 768. [More Information]

2009

• Sutton, I., Lahoria, R., Tan, I., Clouston, P., Barnett, M. (2009). CNS demyelination and quadrivalent HPV vaccination. Multiple Sclerosis: clinical and laboratory research, 15(1), 116-119. [More Information]
• Barnett, M., Parratt, J., Cho, E., Prineas, J. (2009). Immunoglobulins and complement in postmortem multiple sclerosis tissue. Annals of Neurology, 65(1), 32-46. [More Information]
• Barnett, M., Parratt, J., Pollard, J., Prineas, J. (2009). MS: Is it One Disease? The International M S Journal, 16(2), 57-65. [More Information]
• Henderson, A., Barnett, M., Parratt, J., Prineas, J. (2009). Multiple sclerosis: Distribution of inflammatory cells in newly forming lesions. Annals of Neurology, 66(6), 739-753. [More Information]
• Granot, R., Lawrence, R., Barnett, M., Masters, L., Rodriguez, M., Theocharous, C., Pamphlett, R., Hersch, M. (2009). What lies beneath the tent? JC-virus cerebellar granule cell neuronopathy complicating sarcoidosis. Journal of Clinical Neuroscience, 16(8), 1091-2. [More Information]

2007

• McLeod, J., Barnett, M., Macaskill, P., Williams, D. (2007). Long-term prognosis of multiple sclerosis in Australia. Journal of the Neurological Sciences, 256, 35-38. [More Information]

2006

• Barnett, M., Henderson, A., Prineas, J. (2006). The macrophage in MS: just a scavenger after all? Pathology and pathogenesis of the acute MS lesion. Multiple Sclerosis: clinical and laboratory research, 12(2), 121-132. [More Information]
• Patani, (., Barnett, M., Prineas, J. (2006). The pathology of impaired remyelination in multiple sclerosis. 189th Meeting of the Pathological Society of Great Britain and Ireland, United Kingdom: John Wiley & Sons.
• Barnett, M., Sutton, I. (2006). The pathology of multiple sclerosis: a paradigm shift. Current Opinion In Neurology, 19(3), 242-247. [More Information]

2004

• Barnett, M., Prineas, J. (2004). Relapsing And Remitting Multiple Sclerosis: Pathology Of The Newly Forming Lesion. Annals of Neurology, 55(4), 458-468. [More Information]

2003

• Cordato, D., Herkes, G., Mather, L., Morgan, M. (2003). Barbiturates for acute neurological and neurosurgical emergencies – do they still have a role? Journal of Clinical Neuroscience, 10(3), 283-288. [More Information]
• Chan, C., Fryer, J., Herkes, G., Prelog, K., Harrington, T. (2003). Fatal brain stem event complicating acute pancreatitis. Journal of Clinical Neuroscience, 10(3), 351-358. [More Information]
• Barnett, M., Williams, D., Day, S., Macaskill, P., McLeod, J. (2003). Progressive increase in incidence and prevalence of multiple sclerosis in Newcastle, Australia: a 35-year study. Journal of the Neurological Sciences, 213(1-2), 1-6. [More Information]
• Cordato, D., Mather, L., Herkes, G. (2003). Stereochemistry in clinical medicine: a neurological perspective. Journal of Clinical Neuroscience, 10(6), 649-654. [More Information]

2001

• Iland, H., Barnett, M., Pollard, J., Supple, S. (2001). A spontaneous novel XK gene mutation in a patient with McLeod syndrome. British Journal of Haematology, 115, 369-372.